TD Asset Management Inc Acquires 19,000 Shares of HilleVax, Inc. (NASDAQ:HLVX)

TD Asset Management Inc boosted its holdings in HilleVax, Inc. (NASDAQ:HLVX) by 53.9% in the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 54,236 shares of the company’s stock after purchasing an additional 19,000 shares during the quarter. TD Asset Management Inc owned approximately 0.11% of HilleVax worth $784,000 as of its most recent SEC filing.

A number of other institutional investors have also added to or reduced their stakes in HLVX. Rhumbline Advisers boosted its holdings in shares of HilleVax by 27.0% during the 2nd quarter. Rhumbline Advisers now owns 42,658 shares of the company’s stock valued at $617,000 after purchasing an additional 9,073 shares during the last quarter. Bank of New York Mellon Corp boosted its stake in HilleVax by 35.1% during the second quarter. Bank of New York Mellon Corp now owns 93,865 shares of the company’s stock valued at $1,357,000 after buying an additional 24,410 shares during the last quarter. Tidal Investments LLC purchased a new position in HilleVax during the 1st quarter valued at approximately $207,000. EntryPoint Capital LLC bought a new stake in HilleVax in the 1st quarter worth approximately $80,000. Finally, Catalys Pacific LLC purchased a new stake in shares of HilleVax during the 4th quarter worth approximately $21,009,000. 86.42% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Several equities research analysts recently weighed in on HLVX shares. JPMorgan Chase & Co. restated a “neutral” rating and issued a $5.00 price target (down previously from $24.00) on shares of HilleVax in a research report on Monday, July 8th. Stifel Nicolaus downgraded shares of HilleVax from a “buy” rating to a “hold” rating and reduced their target price for the stock from $34.00 to $3.00 in a report on Tuesday, July 9th. HC Wainwright reaffirmed a “neutral” rating and issued a $2.00 price target on shares of HilleVax in a report on Monday, August 12th. Guggenheim cut HilleVax from a “buy” rating to a “neutral” rating in a research note on Monday, July 8th. Finally, Leerink Partners lowered HilleVax from an “outperform” rating to a “market perform” rating and lowered their price objective for the company from $28.00 to $2.00 in a research note on Tuesday, July 9th. Six research analysts have rated the stock with a hold rating, According to MarketBeat, the company presently has an average rating of “Hold” and a consensus price target of $9.20.

HilleVax Price Performance

Shares of NASDAQ:HLVX opened at $1.83 on Monday. The firm has a market capitalization of $90.99 million, a PE ratio of -0.55 and a beta of 0.81. The business has a 50 day simple moving average of $1.79 and a two-hundred day simple moving average of $10.13. HilleVax, Inc. has a 1 year low of $1.55 and a 1 year high of $20.22.

HilleVax (NASDAQ:HLVX) last posted its quarterly earnings data on Thursday, August 8th. The company reported ($0.83) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.73) by ($0.10). Equities research analysts expect that HilleVax, Inc. will post -2.47 EPS for the current fiscal year.

About HilleVax

HilleVax, Inc, a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel vaccines in the United States. It develops HIL-214, a virus-like particle-based vaccine candidate for the prevention of moderate-to-severe acute gastroenteritis caused by norovirus infection. The company was formerly known as MokshaCo, Inc and changed its name to HilleVax, Inc in February 2021.